NO932813L - Peptider som er i stand til aa inhibere aktiviteten av HIV protease, deres fremstilling og deres terapeutiske anvendelse - Google Patents
Peptider som er i stand til aa inhibere aktiviteten av HIV protease, deres fremstilling og deres terapeutiske anvendelseInfo
- Publication number
- NO932813L NO932813L NO932813A NO932813A NO932813L NO 932813 L NO932813 L NO 932813L NO 932813 A NO932813 A NO 932813A NO 932813 A NO932813 A NO 932813A NO 932813 L NO932813 L NO 932813L
- Authority
- NO
- Norway
- Prior art keywords
- inhibiting
- activity
- hiv protease
- hydrogen
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Forbindelser av formel (I): [hvori: R1 er hydrogen, alkyl, aralkyl, -COR", -CORb, -CSR", -CSRb, -S02Rb, -CONHRb, -CSNHR", -CONRbRb eller -CSNR"Rb; R2 er hydrogen eller alkyl; R3 er hydrogen, alkyliden, substituert alkyl, eller Rb; R* er eventuelt substi- tuert alkyl, sykloalkyl eller aryl; R5 er RbO-, RbRbN-, RbHN-, aralkyloksykar- bonyloksy eller aralkyloksykarbonyl- amino, eller R5 er -(CH2 )p-D-(CH2)r- [hvori D er en enkeltbinding, karbonyl, oksygen, svovel, -NH-, -(CH2=CH2)- eller -NHCO-; og E og E er hver O eller et helt tall fra l til 5]; A er -(CH2)m-B- ¿ (CH2)n- [hvori B er en enkeltbinding, karbonyl, oksygen, svovel, -NH-, -(CH2=CHj)- eller -NHCO-; og m og n er hver O eller et helt tall fra l til 5]; R* er alkoksy, aralkyloksy, aryloksy eller alkoksykarbonyl; Rb er eventuelt substituert alkyl, sykloalkyl, hetero- syklisk, aryl eller arylalkenyl]; og farmasøytisk akseptable salter og estere derav og prolegemidler derfor, har evne til å inhibere aktiviteten av HIV-protease og kan således anvendes for behandling og profylakse av AIDS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21174692 | 1992-08-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO932813D0 NO932813D0 (no) | 1993-08-06 |
NO932813L true NO932813L (no) | 1994-02-08 |
Family
ID=16610902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO932813A NO932813L (no) | 1992-08-07 | 1993-08-06 | Peptider som er i stand til aa inhibere aktiviteten av HIV protease, deres fremstilling og deres terapeutiske anvendelse |
Country Status (16)
Country | Link |
---|---|
US (1) | US5629406A (no) |
EP (1) | EP0587311A1 (no) |
KR (1) | KR0177838B1 (no) |
CN (1) | CN1091432A (no) |
AU (1) | AU662434B2 (no) |
CA (1) | CA2103536A1 (no) |
CZ (1) | CZ161993A3 (no) |
FI (1) | FI933472A (no) |
HU (1) | HUT64774A (no) |
IL (1) | IL106600A (no) |
MX (1) | MX9304837A (no) |
NO (1) | NO932813L (no) |
NZ (1) | NZ248332A (no) |
PH (1) | PH31249A (no) |
RU (1) | RU2106357C1 (no) |
ZA (1) | ZA935697B (no) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6313094B1 (en) | 1990-12-11 | 2001-11-06 | Japan Energy Corporation | β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors |
DE69524527D1 (de) * | 1994-10-14 | 2002-01-24 | Japan Energy Corp | AIDS-hemmende Arzneizubereitung und Verfahren |
DE19512484A1 (de) | 1995-04-04 | 1996-10-17 | Bayer Ag | Kohlenhydratmodifizierte Cytostatika |
US6008228A (en) * | 1995-06-06 | 1999-12-28 | Hoffman-La Roche Inc. | Pharmaceutical compositions containing proteinase inhibitors |
CA2179935C (en) * | 1995-06-30 | 2010-09-07 | Ryohei Kato | Novel dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof |
US6222043B1 (en) | 1995-06-30 | 2001-04-24 | Japan Energy Corporation | Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof |
US6291432B1 (en) | 1996-12-27 | 2001-09-18 | Japan Energy Corporation | Tripeptide compounds and anti-AIDS medicine |
JP4006058B2 (ja) | 1997-03-11 | 2007-11-14 | 第一三共株式会社 | 多臓器不全予防及び/又は治療剤 |
DK0950416T3 (da) | 1997-03-14 | 2007-02-26 | Daiichi Seiyaku Co | Anvendelse af TCF-II til behandling af cancerrelateret tab af kropsvægt, anæmi og TNF-forhöjelse |
WO1998051295A1 (fr) * | 1997-05-14 | 1998-11-19 | Nissui Pharmaceutical Co., Ltd. | Inhibiteur de la protease du vih-1, leur procede de production, et compositions medicinales |
ES2147162B1 (es) | 1999-01-27 | 2001-03-16 | Lacer Sa | "s-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias". |
SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
CO5300399A1 (es) | 2000-02-25 | 2003-07-31 | Astrazeneca Ab | Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen |
AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
US7005439B2 (en) | 2000-06-20 | 2006-02-28 | Astrazeneca Ab | Compounds |
GB0104050D0 (en) | 2001-02-19 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
AR035230A1 (es) | 2001-03-19 | 2004-05-05 | Astrazeneca Ab | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos |
GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
SE0101038D0 (sv) | 2001-03-23 | 2001-03-23 | Astrazeneca Ab | Novel compounds |
WO2002081454A1 (en) * | 2001-04-09 | 2002-10-17 | Dr. Reddy's Laboratories Ltd. | Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them |
CN100350036C (zh) | 2001-04-27 | 2007-11-21 | 宝洁公司 | 用于控制生物膜的装置和方法 |
US7094909B2 (en) * | 2001-06-11 | 2006-08-22 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis |
US7169932B2 (en) * | 2001-06-11 | 2007-01-30 | Pfizer Inc. | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis |
HN2002000136A (es) * | 2001-06-11 | 2003-07-31 | Basf Ag | Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis |
SE0103818D0 (sv) | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
KR20040068240A (ko) | 2001-12-14 | 2004-07-30 | 노보 노르디스크 에이/에스 | 호르몬 민감성 리파아제의 활성을 감소시키기 위한 화합물및 그들의 사용 |
SE0301369D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
EP1692104A1 (en) * | 2003-12-04 | 2006-08-23 | Pfizer Inc. | Methods of preparing compounds useful as protease inhibitors |
JP2007513142A (ja) * | 2003-12-04 | 2007-05-24 | ファイザー インコーポレイテッド | プロテアーゼ阻害剤として有用な化合物の製造法 |
WO2005121094A1 (en) * | 2004-06-09 | 2005-12-22 | Pfizer Limited | Piperazine and piperidine derivatives as anti-hiv-agents |
TW200738634A (en) | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
FR2904317A1 (fr) | 2006-07-27 | 2008-02-01 | Inst Nat Sante Rech Med | Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques |
EP2085390A1 (en) | 2008-01-31 | 2009-08-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2056911C (en) * | 1990-12-11 | 1998-09-22 | Yuuichi Nagano | Hiv protease inhibitors |
AU647239B2 (en) * | 1991-02-08 | 1994-03-17 | Sankyo Company Limited | New beta-amino- alpha-hydroxycarboxylic acids and their use |
-
1993
- 1993-08-05 FI FI933472A patent/FI933472A/fi unknown
- 1993-08-05 ZA ZA935697A patent/ZA935697B/xx unknown
- 1993-08-05 NZ NZ248332A patent/NZ248332A/xx unknown
- 1993-08-05 IL IL106600A patent/IL106600A/xx not_active IP Right Cessation
- 1993-08-05 AU AU44438/93A patent/AU662434B2/en not_active Ceased
- 1993-08-06 KR KR1019930015304A patent/KR0177838B1/ko not_active IP Right Cessation
- 1993-08-06 HU HU9302286A patent/HUT64774A/hu unknown
- 1993-08-06 RU RU93050122A patent/RU2106357C1/ru active
- 1993-08-06 NO NO932813A patent/NO932813L/no unknown
- 1993-08-06 EP EP93306258A patent/EP0587311A1/en not_active Withdrawn
- 1993-08-06 CA CA002103536A patent/CA2103536A1/en not_active Abandoned
- 1993-08-06 PH PH46649A patent/PH31249A/en unknown
- 1993-08-06 CZ CZ931619A patent/CZ161993A3/cs unknown
- 1993-08-07 CN CN93117625A patent/CN1091432A/zh active Pending
- 1993-08-09 MX MX9304837A patent/MX9304837A/es unknown
-
1994
- 1994-04-14 US US08/227,588 patent/US5629406A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0587311A1 (en) | 1994-03-16 |
CN1091432A (zh) | 1994-08-31 |
ZA935697B (en) | 1994-03-10 |
AU4443893A (en) | 1994-02-10 |
IL106600A0 (en) | 1993-12-08 |
KR0177838B1 (ko) | 1999-04-01 |
HU9302286D0 (en) | 1993-10-28 |
AU662434B2 (en) | 1995-08-31 |
CA2103536A1 (en) | 1994-02-08 |
US5629406A (en) | 1997-05-13 |
FI933472A (fi) | 1994-02-08 |
IL106600A (en) | 1997-09-30 |
KR940003965A (ko) | 1994-03-14 |
NO932813D0 (no) | 1993-08-06 |
CZ161993A3 (en) | 1994-02-16 |
PH31249A (en) | 1998-06-18 |
NZ248332A (en) | 1995-01-27 |
FI933472A0 (fi) | 1993-08-05 |
MX9304837A (es) | 1994-05-31 |
RU2106357C1 (ru) | 1998-03-10 |
HUT64774A (en) | 1994-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO932813L (no) | Peptider som er i stand til aa inhibere aktiviteten av HIV protease, deres fremstilling og deres terapeutiske anvendelse | |
DE69624081D1 (de) | Matrix-metalloprotease Inhibitoren | |
RU93050122A (ru) | Пептидные соединения, фармацевтическая композиция и способ их получения | |
HUP0301351A2 (hu) | Helyettesített dipeptidszármazékok eljárás az előállításukra alkalmazásuk növekedési hormon szekretagóg hatóanyagokként, és ezeket tartalmazó gyógyszerkészítmények | |
HUP0301249A2 (hu) | APO B termelődés gátló benzamid-vegyületek ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0201088A2 (hu) | Új alfa-aminosav-szulfonil-vegyületek, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
HUP0003921A2 (hu) | VLA-4 által közvetített leukocitaadhéziót gátló szulfonilezett dipeptidszármazékok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
NO874454D0 (no) | Nye derivater av benzimidazoler med anti-ulcusaktivitet og fremgangsmaate for deres fremstilling. | |
DK586588A (da) | Terapeutiske heterocycliske forbindelser | |
NO177638C (no) | Analogifremgangsmåte for fremstilling av en terapeutisk aktiv spiroforbindelse | |
NO180196C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive amino- og nitroholdige, tricykliske forbindelser | |
BG101402A (en) | Apoliprotein-b synthesis inhibitors | |
NO953332L (no) | Nye forbindelser | |
HUP0000894A2 (hu) | Szubsztituált (1,3-bisz(ciklohexilmetil)-1,2,3,6-tetrahidro-2,6-dioxo-9H-purin-8-il)fenil-származékok és eljárás előállításukra | |
PT92554A (pt) | Processo para a preparacao de peptideos inibidores de protease retroviral | |
PE20001495A1 (es) | Derivados de mevinolina | |
MXPA04005940A (es) | Acidos 3-(imidazolil)-2-aminopropanoicos. | |
IL122664A (en) | Esters and amides which are phospholipase A2 inhibitors | |
ATE12933T1 (de) | N-substituierte azaheterocyclische carbonsaeure und ihre ester. | |
NO20024811L (no) | FremgangsmÕte ved syntese av N-[(S)-1-karboksybutyl]-(S)- alaninestere og anvendelse i syntesen av perindopril | |
DE69810800T2 (de) | Azetidinonderivate zur behandlung von hcmv entzündungen | |
NO891484L (no) | Fremgangsmaate for fremstilling av cyklometylen-1,2-bikarboksylsyreamider med terapeutisk aktivitet og farmasoeytiskesammensetninger derav. | |
NO173991C (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktive 1,2,5-ditiazocin-derivater | |
ATE230725T1 (de) | Azetidinonderivate zur behandlung von hcmv entzündungen | |
NO975499L (no) | Form III krystallinsk (R-(R*,R*)-2(4-fluorfenyl)-<beta>-<delta>-dihydroksy-(1-metyl-etyl)-3-fenyl-4-(fenylamino)karbonyl)-1H-pyrrol-1-heptansyre-hemi-kalsiumsalt |